Top

Published in:

01-11-2018 | Epidemiology

Histopathologic characteristics of background parenchymal enhancement (BPE) on breast MRI

Authors: Janice S. Sung, Adriana D. Corben, Jennifer D. Brooks, Marcia Edelweiss, Delia M. Keating, Christine Lin, Elizabeth A. Morris, Prusha Patel, Mark Robson, Meghan Woods, Jonine L. Bernstein, Malcolm C. Pike

Published in: Breast Cancer Research and Treatment | Issue 2/2018

Abstract

Purpose

Breast fibroglandular tissue (FGT), as visualized on a mammogram (mammographic density, MD), is one of the strongest known risk factors for breast cancer. FGT is also visible on breast MRI, and increased background parenchymal enhancement (BPE) in the FGT has been identified as potentially a major breast cancer risk factor. The aim of this exploratory study was to examine the biologic basis of BPE.

Methods

We examined the unaffected contra-lateral breast of 80 breast cancer patients undergoing a prophylactic mastectomy before any treatment other than surgery of their breast cancer. BPE was classified on the BI-RADS scale (minimal/mild/moderate/marked). Slides were stained for microvessel density (MVD), CD34 (another measure of endothelial density), glandular tissue within the FGT and VEGF. Spearman correlations were used to evaluate the associations between BPE and these pathologic variables.

Results

In pre-menopausal patients, BPE was highly correlated with MVD, CD34 and glandular concentration within the FGT, and the pathologic variables were themselves highly correlated. The expression of VEGF was effectively confined to terminal duct lobular unit (TDLU) epithelium. The same relationships of the four pathologic variables with BPE were seen in post-menopausal patients, but the relationships were much weaker and not statistically significant.

Conclusion

The strong correlation of BPE and MVD together with the high correlation of MVD with glandular concentration seen in pre-menopausal patients indicates that increased breast cancer risk associated with BPE in pre-menopausal women is likely to result from its association with increased concentration of glandular tissue in the FGT. The effective confinement of VEGF expression to the TDLUs shows that the signal for MVD growth arises directly from the glandular tissue. Further studies are needed to understand the basis of BPE in post-menopausal women.

Available only for authorised users

McCormack VA, dos Santos Silva I (2006) Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomark Prev 15(6):1159–1169. https://doi.org/10.1158/1055-9965.epi-06-0034 CrossRef

Morris EA (2010) Diagnostic breast MR imaging: current status and future directions. Magn Reson Imaging Clin N Am 18(1):57–74. https://doi.org/10.1016/j.mric.2009.09.005 CrossRefPubMed

King V, Brooks JD, Bernstein JL, Reiner AS, Pike MC, Morris EA (2011) Background parenchymal enhancement at breast MR imaging and breast cancer risk. Radiology 260(1):50–60. https://doi.org/10.1148/radiol.11102156 CrossRefPubMed

Dontchos BN, Rahbar H, Partridge SC, Korde LA, Lam DL, Scheel JR, Peacock S, Lehman CD (2015) Are qualitative assessments of background parenchymal enhancement, amount of fibroglandular tissue on MR images, and mammographic density associated with breast cancer risk? Radiology 276(2):371–380. https://doi.org/10.1148/radiol.2015142304 CrossRefPubMedPubMedCentral

Telegrafo M, Rella L, Stabile Ianora AA, Angelelli G, Moschetta M (2016) Breast MRI background parenchymal enhancement (BPE) correlates with the risk of breast cancer. Magn Reson Imaging 34(2):173–176. https://doi.org/10.1016/j.mri.2015.10.014 CrossRefPubMed

Wu S, Berg WA, Zuley ML, Kurland BF, Jankowitz RC, Nishikawa R, Gur D, Sumkin JH (2016) Breast MRI contrast enhancement kinetics of normal parenchyma correlate with presence of breast cancer. Breast Cancer Res 18(1):76. https://doi.org/10.1186/s13058-016-0734-0 CrossRefPubMedPubMedCentral

Grimm LJ, Saha A, Ghate SV, Kim C, Soo MS, Yoon SC, Mazurowski MA (2018) Relationship between background parenchymal enhancement on high-risk screening MRI and future breast cancer risk. Acad Radiol. https://doi.org/10.1016/j.acra.2018.03.013 CrossRefPubMed

Bennani-Baiti B, Dietzel M, Baltzer PA (2016) MRI background parenchymal enhancement is not associated with breast cancer. PLoS ONE 11(7):e0158573. https://doi.org/10.1371/journal.pone.0158573 CrossRefPubMedPubMedCentral

Hansen NL, Kuhl CK, Barabasch A, Strobel K, Schrading S (2014) Does MRI breast “density” (degree of background enhancement) correlate with mammographic breast density? J Magn Reson Imaging 40(2):483–489. https://doi.org/10.1002/jmri.24495 CrossRefPubMed

10.

King V, Gu Y, Kaplan JB, Brooks JD, Pike MC, Morris EA (2012) Impact of menopausal status on background parenchymal enhancement and fibroglandular tissue on breast MRI. Eur Radiol 22(12):2641–2647. https://doi.org/10.1007/s00330-012-2553-8 CrossRefPubMed

11.

Scaranelo AM, Carrillo MC, Fleming R, Jacks LM, Kulkarni SR, Crystal P (2013) Pilot study of quantitative analysis of background enhancement on breast MR images: association with menstrual cycle and mammographic breast density. Radiology 267(3):692–700. https://doi.org/10.1148/radiol.13120121 CrossRefPubMed

12.

King V, Kaplan J, Pike MC, Liberman L, David Dershaw D, Lee CH, Brooks JD, Morris EA (2012) Impact of tamoxifen on amount of fibroglandular tissue, background parenchymal enhancement, and cysts on breast magnetic resonance imaging. Breast J 18(6):527–534. https://doi.org/10.1111/tbj.12002 CrossRefPubMed

13.

King V, Goldfarb SB, Brooks JD, Sung JS, Nulsen BF, Jozefara JE, Pike MC, Dickler MN, Morris EA (2012) Effect of aromatase inhibitors on background parenchymal enhancement and amount of fibroglandular tissue at breast MR imaging. Radiology 264(3):670–678. https://doi.org/10.1148/radiol.12112669 CrossRefPubMed

14.

Mousa NA, Eiada R, Crystal P, Nayot D, Casper RF (2012) The effect of acute aromatase inhibition on breast parenchymal enhancement in magnetic resonance imaging: a prospective pilot clinical trial. Menopause 19(4):420–425. https://doi.org/10.1097/gme.0b013e31823772a8 CrossRefPubMed

15.

Pfleiderer S, Sachse S, Sauner D, Marx C, Malich A, Wurdinger S, Kaiser W (2004) Changes in magnetic resonance mammography due to hormone replacement therapy. Breast Cancer Res 6(3):R232 R238CrossRef

16.

Delille J-P, Slanetz PJ, Yeh ED, Kopans DB, Halpern EF, Garrido L (2005) Hormone replacement therapy in postmenopausal women: breast tissue perfusion determined with MR imaging—initial observations. Radiology 235(1):36–41. https://doi.org/10.1148/radiol.2351040012 CrossRefPubMed

17.

Reichenbach JR, Przetak C, Klinger G, Kaiser WA (1999) Assessment of breast tissue changes on hormonal replacement therapy using MRI: a pilot study. J Comput Assist Tomogr 23(3):407–413CrossRef

18.

Prentice RL, Chlebowski RT, Stefanick ML, Manson JE, Langer RD, Pettinger M, Hendrix SL, Hubbell FA, Kooperberg C, Kuller LH, Lane DS, McTiernan A, O’Sullivan MJ, Rossouw JE, Anderson GL (2008) Conjugated equine estrogens and breast cancer risk in the Women’s Health Initiative clinical trial and observational study. Am J Epidemiol 167(12):1407–1415. https://doi.org/10.1093/aje/kwn090 CrossRefPubMedPubMedCentral

19.

Lewin AA, Kim SG, Babb JS, Melsaether AN, McKellop J, Moccaldi M, Klautau Leite AP, Moy L (2016) Assessment of background parenchymal enhancement and lesion kinetics in breast MRI of BRCA 1/2 mutation carriers compared to matched controls using quantitative kinetic analysis. Acad Radiol 23(3):358–367. https://doi.org/10.1016/j.acra.2015.11.011 CrossRefPubMedPubMedCentral

20.

DeMartini WB, Liu F, Peacock S, Eby PR, Gutierrez RL, Lehman CD (2012) Background parenchymal enhancement on breast MRI: impact on diagnostic performance. AJR Am J Roentgenol 198(4):W373–W380. https://doi.org/10.2214/AJR.10.6272 CrossRefPubMed

21.

Howe LR, Subbaramaiah K, Hudis CA, Dannenberg AJ (2013) Molecular pathways: adipose inflammation as a mediator of obesity-associated cancer. Clin Cancer Res 19(22):6074–6083. https://doi.org/10.1158/1078-0432.CCR-12-2603 CrossRefPubMedPubMedCentral

22.

Simpson ER, Brown KA (2013) Obesity and breast cancer: role of inflammation and aromatase. J Mol Endocrinol 51(3):T51–T59. https://doi.org/10.1530/JME-13-0217 CrossRefPubMed

23.

Fina L, Molgaard HV, Robertson D, Bradley NJ, Monaghan P, Delia D, Sutherland DR, Baker MA, Greaves MF (1990) Expression of the CD34 gene in vascular endothelial cells. Blood 75(12):2417–2426PubMed

24.

Matsumoto K, Ema M (2014) Roles of VEGF-A signalling in development, regeneration, and tumours. J Biochem 156(1):1–10. https://doi.org/10.1093/jb/mvu031 CrossRefPubMed

25.

Sobolewski C, Cerella C, Dicato M, Ghibelli L, Diederich M (2010) The role of cyclooxygenase-2 in cell proliferation and cell death in human malignancies. Int J Cell Biol. https://doi.org/10.1155/2010/215158 CrossRefPubMedPubMedCentral

26.

Travis MA, Sheppard D (2014) TGF-beta activation and function in immunity. Annu Rev Immunol 32:51–82. https://doi.org/10.1146/annurev-immunol-032713-120257 CrossRefPubMed

27.

Morris PG, Hudis CA, Giri D, Morrow M, Falcone DJ, Zhou XK, Du B, Brogi E, Crawford CB, Kopelovich L, Subbaramaiah K, Dannenberg AJ (2011) Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer. Cancer Prev Res 4(7):1021–1029. https://doi.org/10.1158/1940-6207.CAPR-11-0110 CrossRef

28.

Camerlingo R, Ferraro GA, De Francesco F, Romano M, Nicoletti G, Di Bonito M, Rinaldo M, D’Andrea F, Pirozzi G (2014) The role of CD44+/CD24-/low biomarker for screening, diagnosis and monitoring of breast cancer. Oncol Rep 31(3):1127–1132. https://doi.org/10.3892/or.2013.2943 CrossRefPubMed

29.

Delille JP, Slanetz PJ, Yeh ED, Kopans DB, Garrido L (2005) Physiologic changes in breast magnetic resonance imaging during the menstrual cycle: perfusion imaging, signal enhancement, and influence of the T1 relaxation time of breast tissue. Breast J 11(4):236–241. https://doi.org/10.1111/j.1075-122X.2005.21499.x CrossRefPubMed

30.

Dvorak HF, Harvey VS, Estrella P, Brown LF, McDonagh J, Dvorak AM (1987) Fibrin containing gels induce angiogenesis. Implications for tumor stroma generation and wound healing. Lab Invest 57(6):673–686PubMed

31.

Dvorak HF, Sioussat TM, Brown LF, Berse B, Nagy JA, Sotrel A, Manseau EJ, Van de Water L, Senger DR (1991) Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: concentration in tumor blood vessels. J Exp Med 174(5):1275–1278CrossRef

32.

Roberts WG, Palade GE (1995) Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J Cell Sci 108(Pt 6):2369–2379PubMed

33.

Dellian M, Witwer BP, Salehi HA, Yuan F, Jain RK (1996) Quantitation and physiological characterization of angiogenic vessels in mice: effect of basic fibroblast growth factor, vascular endothelial growth factor/vascular permeability factor, and host microenvironment. Am J Pathol 149(1):59–71PubMedPubMedCentral

34.

Ferrara N, Davis-Smyth T (1997) The biology of vascular endothelial growth factor. Endocr Rev 18(1):4–25. https://doi.org/10.1210/edrv.18.1.0287 CrossRefPubMed

35.

Toi M, Inada K, Suzuki H, Tominaga T (1995) Tumor angiogenesis in breast cancer: its importance as a prognostic indicator and the association with vascular endothelial growth factor expression. Breast Cancer Res Treat 36(2):193–204CrossRef

36.

Li T, Sun L, Miller N, Nicklee T, Woo J, Hulse-Smith L, Tsao MS, Khokha R, Martin L, Boyd N (2005) The association of measured breast tissue characteristics with mammographic density and other risk factors for breast cancer. Cancer Epidemiol Biomark Prev 14(2):343–349CrossRef

37.

Longacre TA, Bartow SA (1986) A correlative morphologic study of human breast and endometrium in the menstrual cycle. Am J Surg Pathol 10:382–393CrossRef

Title: Histopathologic characteristics of background parenchymal enhancement (BPE) on breast MRI
Authors: Janice S. Sung
Adriana D. Corben
Jennifer D. Brooks
Marcia Edelweiss
Delia M. Keating
Christine Lin
Elizabeth A. Morris
Prusha Patel
Mark Robson
Meghan Woods
Jonine L. Bernstein
Malcolm C. Pike
Publication date: 01-11-2018
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 2/2018
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-018-4916-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2018

Fluidic shear stress increases the anti-cancer effects of ROS-generating drugs in circulating tumor cells

Quantifying performance thresholds for recommending screening mammography: a revealed preference analysis of USPSTF guidelines

Genetic polymorphisms of 3′-untranslated region of SULT1A1 and their impact on tamoxifen metabolism and efficacy

Somatic EP300-G211S mutations are associated with overall somatic mutational patterns and breast cancer specific survival in triple-negative breast cancer

Prognostic impact of skeletal muscle volume derived from cross-sectional computed tomography images in breast cancer

Chronologically changing patterns in the survival of korean patients with breast cancer and related clinical factors: a nationwide registry-based study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer